New eczema drug shows promise in Mid-Stage trial

NCT ID NCT07277660

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated Apr 25, 2026 · Updated 16 times

Summary

This study tests a new medicine called galvokimig in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if different doses can reduce skin redness, itching, and rash better than a placebo. Participants will receive either the drug or a placebo for 16 weeks, and doctors will measure improvement using standard eczema scores.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Atd002 21001
RECRUITING

Habikino, Japan
Atd002 21004
RECRUITING

Tachikawa-shi, Japan
Atd002 21005
RECRUITING

Sakai, Japan
Atd002 21006
RECRUITING

Yokohama, Japan
Atd002 21007
RECRUITING

Nagoya, Japan
Atd002 21008
RECRUITING

Sapporo, Japan
Atd002 41001
RECRUITING

Pleven, Bulgaria
Atd002 41002
RECRUITING

Sevlievo, Bulgaria
Atd002 41004
RECRUITING

Lovech, Bulgaria
Atd002 41005
RECRUITING

Sofia, Bulgaria
Atd002 41006
RECRUITING

Sofia, Bulgaria
Atd002 42001
RECRUITING

Prague, Czechia
Atd002 42002
RECRUITING

Náchod, Czechia
Atd002 42004
RECRUITING

Prague, Czechia
Atd002 42005
RECRUITING

Prague, Czechia
Atd002 43004
RECRUITING

Leipzig, Germany
Atd002 43007
RECRUITING

Mahlow, Germany
Atd002 44003
RECRUITING

Budapest, Hungary
Atd002 45002
RECRUITING

Warsaw, Poland
Atd002 45003
RECRUITING

Krakow, Poland
Atd002 45004
RECRUITING

Warsaw, Poland
Atd002 45005
RECRUITING

Sosnowiec, Poland
Atd002 45006
RECRUITING

Warsaw, Poland
Atd002 45007
RECRUITING

Krakow, Poland
Atd002 45008
RECRUITING

Wroclaw, Poland
Atd002 45009
RECRUITING

Tarnów, Poland
Atd002 45014
RECRUITING

Krakow, Poland
Atd002 46003
RECRUITING

Salford, United Kingdom
Atd002 46004
RECRUITING

London, United Kingdom
Atd002 51006
RECRUITING

Hamilton, Canada
Atd002 51007
RECRUITING

Toronto, Canada
Atd002 52001
RECRUITING

Troy, Michigan, 48084, United States
Atd002 52003
RECRUITING

Miami, Florida, 33133, United States
Atd002 52004
RECRUITING

Sugar Land, Texas, 77479, United States
Atd002 52005
RECRUITING

Dallas, Texas, 75230, United States
Atd002 52007
RECRUITING

Coral Gables, Florida, 33134, United States
Atd002 52008
RECRUITING

Santa Monica, California, 90404, United States
Atd002 52009
RECRUITING

Troy, Michigan, 48084, United States
Atd002 52010
RECRUITING

Omaha, Nebraska, 68144, United States
Atd002 52011
RECRUITING

Frisco, Texas, 75034, United States
Atd002 52012
RECRUITING

New Albany, Indiana, 47150, United States
Atd002 52013
RECRUITING

Boca Raton, Florida, 33486, United States
Atd002 52014
RECRUITING

Bowling Green, Kentucky, 42104, United States
Atd002 52015
RECRUITING

Savannah, Georgia, 31419, United States
Atd002 52016
RECRUITING

Frisco, Texas, 75033, United States
Atd002 52017
RECRUITING

Chicago, Illinois, 60611, United States
Atd002 52018
RECRUITING

Wheaton, Illinois, 60189, United States
Atd002 52019
RECRUITING

Philadelphia, Pennsylvania, 19114, United States
Atd002 52020
RECRUITING

The Bronx, New York, 10455, United States
Atd002 52021
RECRUITING

Oceanside, California, 92056, United States

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS